Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lamazym in Alpha-Mannosidosis
NCT01681953Phase 3Completed
- Sponsor
- Zymenex
- Start
- Aug 2012
- Primary completion
- May 2014
- Modality
- Replacement Enzymes
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in alpha-mannosidosis comparing Lamazym with Placebo (2 arms). Primary endpoints: Reduction of oligosaccharides in serum at 52 weeks and 3-minute stair climb test at 52 weeks. Started Aug 2012; status: completed.
02
Drugs
velmanase alfa
03
Conditions
alpha-mannosidosis
Beyond the preview
Go deeper on NCT01681953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01681953.